- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05214339
A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)
A Prospective, Single-arm, Multicenter, Phase II Trial to Evaluate the Effectiveness and Safety of Hepatic Arterial Infusion Chemotherapy (HAIC) of Oxaliplatin, 5-fluorouracil and Leucovorin (mFOLFOX7) Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification
This study was designed to evaluate the effectiveness and safety of hepatic arterial infusion chemotherapy combined with Bevacizumab and Sintilimab (Triplet-combined Therapy) for Unresectable A-staged Hepatocellular Carcinoma in BCLC classification.
The primary outcome measure is to evaluate the objective response rate (ORR RECIST 1.1) of Triplet-combined Therapy for Unresectable A-staged Hepatocellular Carcinoma in BCLC classification.
The secondary Outcome measures include the objective response rate (ORR mRECIST 1.1), duration of response (DOR), disease control rate (DCR), progression-free survival rate (PFSR) [ Time Frame: 6- and 12-month], overall survival rate (OSR) [ Time Frame: 6- and 12-month], the median progression-free survival time (mPFS) and median overall survival time (mOS) of Triplet-combined Therapy for Unresectable A-staged Hepatocellular Carcinoma in BCLC classification.
Moreover, this study aims to assess the safety and tolerability of Triplet-combined Therapy for Unresectable A-staged Hepatocellular Carcinoma in BCLC classification.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Yang-Kui Gu, Prof.
- Phone Number: +862087345272
- Email: guyk@sysucc.org.cn
Study Contact Backup
- Name: Meng-Xuan Zuo, Dr.
- Email: zuomx@sysucc.org.cn
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Recruiting
- Yang-Kui Gu
-
Contact:
- Yang-Kui Gu, Prof.
- Phone Number: 13822197618 +862087343272
- Email: guyk@sysucc.org.cn
-
Contact:
- Meng-xuan Zuo, Dr.
- Phone Number: 18924266069 18924266069
- Email: zuomx@sysucc.org.cn
-
Guangzhou, Guangdong, China, 510120
- Not yet recruiting
- Sun Yat-sen Memorial Hospital
-
Contact:
- Zhi-yu Xiao, Prof.
- Phone Number: 13682283695 13682283695
-
Guangzhou, Guangdong, China, 510510
- Not yet recruiting
- Nanfang Hospital of Southern Medical University
-
Contact:
- Jing-zhang Chen, Prof.
- Phone Number: 13802522545 13802522545
-
Guanzhou, Guangdong, China, 510630
- Not yet recruiting
- The Third Affiliated Hospital of Sun Yat-sen University
-
Contact:
- Nan Lin, Prof.
- Phone Number: 13925027138 13925027138
-
-
Hunan
-
Changsha, Hunan, China, 410013
- Not yet recruiting
- Xiangya Hospital of Central South University
-
Contact:
- Liang-rong Shi, Prof.
- Phone Number: 13974886662 13974886662
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patient voluntarily joins the study and signs an informed consent;
- Age≥18 years old, ≤70 years old, both men and women;
- Clinical or pathologically confirmed unresectable BCLC A-stage hepatocellular carcinoma, no further anti-tumor treatment;
- Child-Pugh score small or equal to 6 points (Child-Pugh A-B);
- ECOG score: 0 to 1 (according to the ECOG score classification);
- The expected survival is longer than 12 weeks;
The laboratory parameters meets the following requirements (no blood components and cell growth factors are allowed within 14 days before the first dose):
- Absolute neutrophil count≥3.0×109 / L;
- Platelets≥80×109 / L;
- Hemoglobin≥90 g / L;
- serum albumin≥28 g / L;
- Thyroid stimulating hormone (TSH)≤1×ULN (if abnormalities should be considered at the same time FT3, FT4 levels, patients with FT3 and FT4 levels in normal range can also be enrolled);
- bilirubin≤1.5×ULN (within 7 days prior to the first dose);
- ALT≤3 x ULN and AST≤3 x ULN (within 7 days prior to the first dose);
- AKP≤2.5×ULN; serum creatinine≤1.5×ULN;
- For female that non-surgical sterilization or in childbearing age need to use a medically approved contraceptive (such as an intrauterine device, contraceptive or condom) during the study period and within 3 months after the end of the study treatment period; For female that non-surgical sterilization or in childbearing age must have a negative serum or urine HCG test within 72 hours prior to study enrollment; and must be nonlactating; for male patients whose partner in a childbearing age, effective methods of contraception should be given during the trial and at the end of Sintilimab injection.
Exclusion Criteria:
- The patient has any active auto-immune disease or a history of autoimmune disease (such as the following, but not limited to: auto-immune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, thyroid hyperfunction; patients with vitiligo. For patient with history of asthma, complete remission of asthma in childhood without any intervention after adulthood can be included, while those asthma patients who require bronchodilators for medical intervention cannot be included.);
- The patient is using immunosuppressive agents or systemic hormonal therapy for immunosuppression purposes (dose > 10 mg/day of prednisone or other therapeutic hormones) and continues to be used within 2 weeks prior to enrollment;
- Severe allergic reactions to other monoclonal antibodies;
- Known for a history of central nervous system metastasis or hepatic encephalopathy;
- Having a history of organ transplantation;
- Patients with clinically symptomatic ascites who require puncture, drainage, or ascites drainage within 3 months, except for those who have a small amount of ascites but no clinical symptoms;
- Suffering from hypertension, and cannot be well controlled by antihypertensive drugs (systolic blood pressure≥140mmHg or diastolic blood pressure≥90 mmHg);
- Suffering heart diseases with clinical symptoms or those not well controlled, such as: (1) heart failure in NYHA class 2 or higher; (2) unstable angina; (3) myocardial infarction occurred within 1 year; (4) clinically symptomatic supraventricular or ventricular arrhythmia requiring treatment or intervention; (5) Tc > 450ms (male); Tc > 470ms (female);
- Coagulation dysfunction (INR>2.0, PT>16s), bleeding tendency or receiving thrombolysis or anticoagulant therapy, allowing prophylactic use of low-dose aspirin or low molecular heparin;
- There are significant clinically significant bleeding symptoms or clear bleeding tendency within 3 months before enrollment, such as hemoptysis of 2.5ml or more per day, gastrointestinal bleeding, esophageal varices with bleeding risk, hemorrhagic gastric ulcer or vasculitis, etc. If the fecal occult blood is positive in the baseline period, it can be watched, then gastroscope is needed for those fecal occult blood is still positive. If the gastroscope indicates severe esophageal varices, it cannot be enrolled, except for those who have undergone gastroscopy within a month or less to exclude such cases);
- Events of arterial/venous thrombosis occurring within the first 6 months of enrollment, such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism;
- There are known hereditary or acquired bleeding and thrombophilia (such as hemophilia patients, coagulopathy, thrombocytopenia, etc.);
- Urine routine indicates that urine protein≥++ and 24-hour urine protein amount > 1.0g was confirmed;
- The patient has active infection, unexplained fever (≥38.5°C) within 3 days before administration, or baseline white blood cell count>15×109/L;15 Patients with congenital or acquired immunodeficiency (such as HIVinfected patients);
- HBV-DNA>2000 IU/ml (or 104 copies/ml); or HCV-RNA>103 copies/ml; or HBsAg+ and anti-HCV antibody positive patients;
- The patient has had other malignant tumors in the past 3 years or at the same time (except for cured skin basal cell carcinoma and cervical carcinoma in situ);
- Patients with bone metastases who had received palliative radiotherapy >4% of the bone marrow area within 4 weeks prior to participation in the study;
- Patients have previously received other anti-PD-1 antibody therapy or other immunotherapy against PD-1/PD-L1, or have received apatinib before;
- Inoculation of a live vaccine within less than 4 weeks prior to study or possibly during the study period;
- Pregnant or lactating women, or women of childbearing age who are unwilling to take contraceptive measures;
- According to the investigators, the patient has other factors that may affect the results of the study or lead to the termination of the study, such as alcohol abuse, drug abuse, other serious diseases (including mental illness) requiring combined treatment, and serious laboratory tests, abnormalities, accompanied by factors such as family or society, which may affect the safety of enrolled patients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TRIPLET
Combination Product: Hepatic Arterial Infusion combined with Bevacizumab and Sintilimab Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Bevacizumab and Sintilimab for injection. Procedure: 1. On the first day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX7, oxaliplatin 85 mg/m2 2 hours, folinic acid 400 mg/m2, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 6 times. 2. Intravenous infusion of Bevacizumab 7.5mg/kg every 3 weeks on the 4th day. 3. On the 25nd day of treatment, namely the second session of HAIC, intravenous infusion of Sintilimab 200mg every 3 weeks. 4. The cumulative maximum drug use period is up to 1 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear. |
The patient will receive Hepatic Arterial Infusion(mFOLFOX7) on the first day, and intravenous infusion of Bevacizumab on the 4th day, and intravenous infusion of Sintilimab on the 25th day.
The intervention is repeated every 3 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR) by RECIST 1.1
Time Frame: From date of first dose of study drug until disease progression, development of unacceptable toxicity, withdrawal of consent, or sponsor termination (up to approximately 3 years)
|
ORR is defined as the percentage of participants who have best overall response (BOR) of complete response (CR) or partial response (PR) at the time of data cutoff as assessed by RECIST 1.1
|
From date of first dose of study drug until disease progression, development of unacceptable toxicity, withdrawal of consent, or sponsor termination (up to approximately 3 years)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR) by mRECIST
Time Frame: From date of first dose of study drug until disease progression, development of unacceptable toxicity, withdrawal of consent, or sponsor termination (up to approximately 3 years)
|
ORR is defined as the percentage of participants who have best overall response (BOR) of complete response (CR) or partial response (PR) at the time of data cutoff as assessed by mRECIST
|
From date of first dose of study drug until disease progression, development of unacceptable toxicity, withdrawal of consent, or sponsor termination (up to approximately 3 years)
|
The disease control rate (DCR)
Time Frame: From date of first dose of study drug until disease progression, stable disease, development of unacceptable toxicity, withdrawal of consent, or sponsor termination (up to approximately 3 years)
|
DCR is defined as the percentage of participants who have best overall response (BOR) of complete response (CR) or partial response (PR) or stable disease (SD) at the time of data cutoff as assessed by RECIST 1.1 and mRECIST
|
From date of first dose of study drug until disease progression, stable disease, development of unacceptable toxicity, withdrawal of consent, or sponsor termination (up to approximately 3 years)
|
Duration of response (DOR) by RECIST 1.1 and mRECIST
Time Frame: From the first documentation of CR or PR to the first date of documentation of disease progression or death whichever occurs first (up to approximately 3 years)
|
DOR is defined as the time from the first documentation of CR or PR to the date of first documentation of disease progression or death (whichever occurs first) as assessed by RECIST 1.1 and mRECIST
|
From the first documentation of CR or PR to the first date of documentation of disease progression or death whichever occurs first (up to approximately 3 years)
|
The progression-free survival rate (PFSR) by RECIST 1.1 and mRECIST
Time Frame: From date of first dose of study drug to the date of first documentation of disease progression or death, whichever occurs first (up to approximately 3 years)
|
From date of first dose of study drug to the date of first documentation of disease progression or death, whichever occurs first (up to approximately 3 years)
|
|
The overall survival rate (OSR)
Time Frame: From date of first dose of study drug to the date of first documentation of death from any cause, whichever occurs first (up to approximately 3 years)
|
From date of first dose of study drug to the date of first documentation of death from any cause, whichever occurs first (up to approximately 3 years)
|
|
The progression-free survival time (mPFS)
Time Frame: From date of first dose of study drug to the date of first documentation of disease progression (up to approximately 3 years)
|
The progression-free survival time (mPFS) defined as the time from the first study dose date to the date of first documentation of disease progression as assessed by RECIST 1.1 and mRECIST
|
From date of first dose of study drug to the date of first documentation of disease progression (up to approximately 3 years)
|
The median overall survival time (mOS)
Time Frame: From the start date of the Treatment Phase until date of death from any cause (up to approximately 3 years)
|
OS is measured from the start date of the Treatment Phase (date of first study dose) until date of death from any cause.
Participants who are lost to follow-up and the participants who are alive at the date of data cutoff will be censored at the date the participant was last known alive or the cut-off date, whichever comes earlier.
|
From the start date of the Treatment Phase until date of death from any cause (up to approximately 3 years)
|
Surgical conversion rate
Time Frame: From the start date of the Treatment Phase until date of Surgical resection(up to approximately 20 weeks)
|
From the start date of the Treatment Phase until date of Surgical resection(up to approximately 20 weeks)
|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: From the start date of the Treatment Phase until date of death from any cause (up to approximately 3 years)
|
From the start date of the Treatment Phase until date of death from any cause (up to approximately 3 years)
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Liver Diseases
- Liver Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Bevacizumab
Other Study ID Numbers
- D-TRIPLET
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Unresectable Hepatocellular Carcinoma
-
National Cancer Institute (NCI)Active, not recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Hepatocellular Carcinoma | Metastatic Cholangiocarcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular... and other conditionsUnited States
-
BeiGeneCompletedHepatocellular Carcinoma | Unresectable Hepatocellular Carcinoma | Metastatic Hepatocellular CarcinomaChina
-
H. Lee Moffitt Cancer Center and Research InstituteNational Comprehensive Cancer NetworkWithdrawnLiver Cancer | HepatoCellular Carcinoma | Unresectable HepatoCellular CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic CholangiocarcinomaUnited States
-
Mayo ClinicRecruitingAdvanced Hepatocellular Carcinoma | Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8United States
-
Sirtex MedicalBright Research PartnersRecruitingUnresectable Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityWithdrawnUnresectable Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Locally Advanced Hepatocellular Carcinoma
-
Chengdu New Radiomedicine Technology Co. LTD.RecruitingUnresectable Hepatocellular CarcinomaChina
-
BayerRecruitingUnresectable Hepatocellular CarcinomaGreece, Brazil, China, Colombia, Italy, Korea, Republic of, Saudi Arabia, Spain, Taiwan, Thailand, United States, Argentina, France, Mexico, Turkey
-
Zhongda HospitalRecruitingUnresectable Hepatocellular CarcinomaChina
Clinical Trials on Hepatic Arterial Infusion(mFOLFOX7) combined with Bevacizumab and Sintilimab
-
Sun Yat-sen UniversityCompletedHepatocellular CarcinomaChina
-
Sun Yat-sen UniversityJiangsu HengRui Medicine Co., Ltd.RecruitingC-staged Hepatocellular Carcinoma in BCLC ClassificationChina
-
Sun Yat-sen UniversityRecruiting
-
Sun Yat-sen UniversityRecruitingHepatocellular CarcinomaChina
-
Sun Yat-sen UniversityJiangsu HengRui Medicine Co., Ltd.RecruitingC-staged Hepatocellular Carcinoma in BCLC ClassificationChina
-
Sun Yat-sen UniversityCompletedHepatocellular CarcinomaChina
-
Tianjin Medical University Cancer Institute and...Not yet recruitingColorectal Cancer | Liver Metastasis
-
Sun Yat-sen UniversityRecruitingHepatocellular Carcinoma | PD-1 Inhibitor | Lenvatinib | Hepatic Arterial Infusion ChemotherapyChina
-
Peking University Cancer Hospital & InstituteRecruitingLiver Metastasis Colon Cancer | Advanced Colorectal CarcinomaChina
-
Tianjin Medical University Cancer Institute and...RecruitingHepatocellular CarcinomaChina